Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more
Zealand Pharma A/S (ZLDPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.070x
Based on the latest financial reports, Zealand Pharma A/S (ZLDPF) has a cash flow conversion efficiency ratio of -0.070x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.58 Million) by net assets ($999.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zealand Pharma A/S - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Zealand Pharma A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zealand Pharma A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zealand Pharma A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Siam Cement Public Company Limited
PINK:SCVPF
|
0.041x |
|
Allreal Holding
SW:ALLN
|
0.034x |
|
Kyowa Kirin Co. Ltd
PINK:KYKOF
|
0.034x |
|
BGC Group Inc.
NASDAQ:BGC
|
0.124x |
|
Impulsora del Desarrollo y el Empleo en América Latina S.A.B. de C.V
MX:IDEALB-1
|
0.022x |
|
NH Foods Ltd
F:NI6
|
0.048x |
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY
|
0.025x |
|
Enerjisa Enerji AS
IS:ENJSA
|
0.063x |
Annual Cash Flow Conversion Efficiency for Zealand Pharma A/S (2007–2024)
The table below shows the annual cash flow conversion efficiency of Zealand Pharma A/S from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.62 Billion | $-930.82 Million | -0.108x | +59.58% |
| 2023-12-31 | $1.59 Billion | $-425.67 Million | -0.267x | +76.86% |
| 2022-12-31 | $815.91 Million | $-942.21 Million | -1.155x | +11.60% |
| 2021-12-31 | $927.80 Million | $-1.21 Billion | -1.306x | -123.26% |
| 2020-12-31 | $1.18 Billion | $-688.72 Million | -0.585x | -77.57% |
| 2019-12-31 | $1.24 Billion | $-409.45 Million | -0.329x | +20.11% |
| 2018-12-31 | $1.12 Billion | $-460.40 Million | -0.412x | +21.81% |
| 2017-12-31 | $528.47 Million | $-278.75 Million | -0.527x | -458.73% |
| 2016-12-31 | $278.19 Million | $40.90 Million | 0.147x | +116.45% |
| 2015-12-31 | $252.23 Million | $-225.41 Million | -0.894x | -435.63% |
| 2014-12-31 | $252.83 Million | $-42.18 Million | -0.167x | +68.90% |
| 2013-12-31 | $316.14 Million | $-169.62 Million | -0.537x | -484.38% |
| 2012-12-31 | $491.01 Million | $68.54 Million | 0.140x | +3511.47% |
| 2011-12-31 | $441.40 Million | $-1.81 Million | -0.004x | +97.02% |
| 2010-12-31 | $407.11 Million | $-55.98 Million | -0.138x | +70.26% |
| 2009-12-31 | $132.92 Million | $-61.45 Million | -0.462x | -237.00% |
| 2008-12-31 | $208.63 Million | $-28.62 Million | -0.137x | +42.25% |
| 2007-12-31 | $242.37 Million | $-57.57 Million | -0.238x | -- |